Clinical Trial

Immune Metabolism Dysregulation and Efficacy to Anti-PD-1 PD-L1 Agents in Non Small Cell Lung Cancer Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 9, 2026 (before its estimated July 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
Prospective, biological, observational study involving the collection and use of samples from patients suffering from NSCLC lung cancer, aimed at comparing the molecular profile related to metabolism among subjects with response or resistance to checkpoint inhibitors immune system (ICI), in order to contribute to define response biomarkers and new molecular pathways as therapeutic targets combine with ICI to overcome resistance.
Trial Details
NCT Number NCT07637474
Lead Sponsor Regina Elena Cancer Institute
Collaborators: Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Conditions Nsclc
Enrollment 150 participants
Start Date 2024-07-24
Primary Completion 2026-07-24 (estimated)
Study Completion 2026-07-24 (estimated)
Updated on ClinicalTrials.gov 2026-06-09